EGFR and cancer: The in vitro studies showed that our optimized DTPA-derivatized NMs were able to perfectly protect the formulated siRNA and preserve their active targeting properties, as reflected by a 1.7-fold higher siRNA transfection efficiency level in EGFR-positive cancer cells compared to non-targeted NMs.